Safety and Efficacy of Intensity-Modulated Stereotactic Body Radiotherapy Using Helical Tomotherapy for Lung Cancer and Lung Metastasis

Table 1

Patient characteristics.

Characteristic	Number of patients (%)
	Total	4 fractions	5–8 fractions	𝑃 value
Total number of patients	72	37	35
Gender
Male	47 (65)	24 (51)	23 (49)	1.0
Female	25 (35)	13 (52)	12 (48)
Age (years), median [range]	76 [31–93]	76 [31–93]	78 [51–90]	0.17
Follow-up (months), median [range]	20 [6–46]	20 [7–41]	21 [6–46]	0.74
Clinical stage
Primary
cT1N0M0	52	30	22
cT2N0M0	1	0	1
Metastasis	12*	4	8
Recurrence	7	3	4
Performance status
0	61 (85)	34 (56)	27 (44)	0.15
1	9 (12)	3 (33)	6 (67)
2	2 (3)	0	2
Previous radiotherapy
Yes	23 (32)	11 (48)	12 (52)	0.8
No	49 (68)	26 (53)	23 (47)
Previous operation
Yes	28 (39)	12 (43)	16 (57)	0.33
No	44 (61)	25 (57)	19 (43)
Previous chemotherapy
Yes	3 (4)	1 (33)	2 (67)	0.61
No	69 (96)	36 (52)	33 (48)
Double cancer
Yes	24 (33)	12 (50)	12 (50)	1.0
No	48 (67)	25 (52)	23 (48)

∗Primary organ: tongue in 1, lung in 3, esophagus in 1, liver in 1, colorectum in 3, and ovary in 3.